CanBas Co., Ltd.
CanBas Co., Ltd. scores highest on Nitro (64) and lowest on Price (2). Its PosiPenta is 28.91 out of 100, weaker than most similar companies.
On the Penta Grid this week, CanBas Co., Ltd. is Grid #70 of 91 in the Healthcare sector in Japan, and Grid #1,247 of 1,383 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| CanBas Co., Ltd. | 28.91 | 2 | 9 | 64 | 51 | 19 |
| HYUGA PRIMARY CARE Co.,Ltd. | 56.04 | 17 | 65 | 100 | 56 | 43 |
| Japan Medical Dynamic Marketing, INC. | 36.57 | 47 | 53 | 24 | 25 | 34 |
| Renascience Inc. | 25.34 | 8 | 16 | 13 | 56 | 34 |
| RaQualia Pharma Inc. | 33.16 | 20 | 58 | 23 | 35 | 30 |
| Ohki Healthcare Holdings Co.,Ltd. | 46.77 | 69 | 50 | 24 | 29 | 61 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -11.62 |
| P/B ratio | 9.28 |
EEarnings
| Trailing EPS | ₹-40.19 |
| Forward EPS | — |
NNitro
| Price | 467.05 |
| 52-week high | 598.77 |
| 52-week low | 305.73 |
| Fall from 52-week high | 22.0% |
TTorque
| Return on equity (ROE) | -57.07% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | -0.83 |
| Market cap | ₹920 Cr |
| Insider holding | 7.16% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is CanBas Co., Ltd.'s PosiPenta score?
CanBas Co., Ltd.'s PosiPenta is 28.91 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does CanBas Co., Ltd. stand on the Penta Grid?
On the Penta Grid this week, CanBas Co., Ltd. is Grid #70 of 91 in the Healthcare sector in Japan, and Grid #1,247 of 1,383 in Japan.
Which PosiPenta pillar is strongest for CanBas Co., Ltd.?
Nitro (momentum), with a score of 64 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for CanBas Co., Ltd.?
Price (valuation), with a score of 2 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.